Hepatocellular carcinoma (HCC) is an aggressive primary liver malignancy often diagnosed at an advanced stage, resulting in a poor prognosis. Accurate risk stratification and early detection of HCC are critical unmet needs for improving outcomes. Several blood-based biomarkers and imaging tests are available for early detection, prediction, and monitoring of HCC. However, serum protein biomarkers such as alpha-fetoprotein have shown relatively low sensitivity, leading to inaccurate performance. Imaging studies also face limitations related to suboptimal accuracy, high cost, and limited implementation. Recently, liquid biopsy techniques have gained attention for addressing these unmet needs. Liquid biopsy is non-invasive and provides more objective readouts, requiring less reliance on healthcare professional’s skills compared to imaging. Circulating tumor cells, cell-free DNA, and extracellular vesicles are targeted in liquid biopsies as novel biomarkers for HCC. Despite their potential, there are debates regarding the role of these novel biomarkers in the HCC care continuum. This review article aims to discuss the technical challenges, recent technical advancements, advantages and disadvantages of these liquid biopsies, as well as their current clinical application and future directions of liquid biopsy in HCC.
Citations
Citations to this article as recorded by
Therapeutic effects of the n-butanol extract of Potentilla freyniana Bornm. in hepatocellular carcinoma cells Yan Wang, Zaiqi Zhang, Liang Cao, Sisi Huang, Xi Huang, Ziyang Zhang, Yanbin Zhang, Xiang Li Journal of Ethnopharmacology.2026; 354: 120492. CrossRef
Liver cancer stem cells as novel diagnostic biomarkers Qamar Abuhassan, Omer Qutaiba B. Allela, Radhwan Abdul Kareem, Soumya V. Menon, Priya Priyadarshini Nayak, J. Bethanney Janney, Vimal Arora, Aashna Sinha, Hayder Naji Sameer, Atheer Khdyair Hamad, Zainab H. Athab, Mohaned Adil Clinica Chimica Acta.2026; 580: 120739. CrossRef
Clinical utilization of testing for cell-free DNA in hepatocellular cancer Jasmine J. Wang, Yi-Te Lee, Amy K. Kim, Augusto Villanueva, Amit G. Singal, Ju Dong Yang Hepatology.2026; 84(4): 1096. CrossRef
Targeting copper death-related long non-coding RNAs: a novel strategy to overcome immunotherapy resistance in liver cancer Xiyang Sheng, Chen Mi, Gengyuan Shi, Longbo Wang, Yongzhao Li, Dongdong Wang, Wei Wang, Yongyue Du, Siyang Wang, Hanteng Yang Frontiers in Immunology.2026;[Epub] CrossRef
Synergistic role of multi-omics analysis combined with multimodal imaging in precision diagnosis and treatment of thoracic and abdominal tumors Bin Su, Junshan Li, Jie Zhang, Tao Deng, Zheng Fang, Yuanlong Wang Current Radiopharmaceuticals.2026; 19(3): 100040. CrossRef
Artificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care Sherihan G. AbdelHamid, Esraa M. Halawa, Eman M. Ibrahim, Mahmoud ElHefnawi Cancer Cell International.2026;[Epub] CrossRef
Plasma exosome-derived tsRNAs as a novel noninvasive biomarker for early detection and prognosis prediction of hepatocellular carcinoma Lin Ding, Yini Li, Te Liu, Xinyi He, Ying Zhao, Baishen Pan, Wenjing Yang, Xinrong Yang, Wei Guo, Beili Wang Genes & Diseases.2026; : 102180. CrossRef
Exploring single-cell and multi-omics technologies and their role in unraveling tumor heterogeneity of hepatocellular carcinoma Charmi Jyotishi, Suresh Prajapati, Mansi Patel, Reeshu Gupta Journal of Liver Cancer.2026; 26(1): 104. CrossRef
Small Extracellular Vesicle‐Associated Polymeric Immunoglobulin Receptor in Primary Liver Cancer: From Immunological Mediator to Oncogenic Driver and Biomarker Jeremy Ting Ruei Hsu, Samuel Wan Ki Wong, Judy Yam Wai Ping Cell Proliferation.2026;[Epub] CrossRef
Liver Dysfunction Explains a Substantial Proportion of Circulating cfDNA Variability in HCC: An Exploratory Study Ioana Manea, Speranta Maria Iacob, Razvan Iacob, Alina-Veronica Ghionescu, Andrei Sorop, Roxana Elena Saizu, Daria-Ana-Arina Gheorghe, Delia Prisecariu, Simona Olimpia Dima, Liliana Simona Gheorghe Biomedicines.2026; 14(7): 1561. CrossRef
Correspondence to letter to the editor on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1+KLRC2-CD16hi subset linked to hepatitis B virus outcomes” Zihan Jin, Libo Tang, Yuhao Wang, Shihong Zhong, Yongyin Li Clinical and Molecular Hepatology.2026; 32(3): e427. CrossRef
Circulating tumor DNA for minimal residual disease and recurrence surveillance in hepatocellular carcinoma: current evidence and a translational roadmap Yang Gu, Xiaofeng Luo, Yuxian Zhang, Jie Tang, Zhigang Wang Frontiers in Oncology.2026;[Epub] CrossRef
Molecular biomarkers for early-stage hepatocellular carcinoma: Clinical applications beyond alpha-fetoprotein Marah Amer, Valeria Tosello, Elisa Pinto The International Journal of Biological Markers.2026;[Epub] CrossRef
The Rationale for Tissue Biopsy in the Era of Precision Hepatocellular Carcinoma Management Ioanna-Maria Grypari, Dina G. Tiniakos, Maria Kalafateli, Eleni Theocharidou Cancers.2026; 18(19): 3115. CrossRef
Liquid biopsy: Fundamental principles and clinical value in hepatocellular carcinoma Anil Chandra Anand, Dibyalochan Praharaj, Preetam Nath Journal of Integrative Medicine and Research.2025; 3(3): 148. CrossRef
Prognostic Significance of Liquid Biopsy-Detected Genetic Alterations in Hepatocellular Carcinoma Ahmet Gökhan Sarıtaş, Burak Yavuz, İshak Aydın, Harun Ağca, Uğur Topal, Tuğsan Ballı, Atil Bisgin, Abdullah Ülkü, Atılgan Tolga Akçam Journal of Hepatocellular Carcinoma.2025; Volume 12: 2035. CrossRef
Electrochemical Biosensor Based on a Tetrahedral DNA Nanostructure and an “AND” Logic Gate-Regulated Cascade Amplification System for Parallel Detection of Dual Disease Biomarkers Li Yang, Ya Zhou, Huimin Li, Yao Gao, Xiaoli Xiong, Tao Zhang, Liping Zhu, Xiurong Yang ACS Sensors.2025; 10(10): 7744. CrossRef
Machine Learning-based Gene Biomarker Identification for Improving Prognosis and Therapy in Hepatocellular Carcinoma Lingyan Deng, Lei Dou, Xinyu Huang, Peng Wang, Na Shen Current Medicinal Chemistry.2025; 32(39): 8975. CrossRef
Preclinical Studies on the Photothermal Therapy of NIR‐II AIEgens: Across Tumor Types Zijuan Meng, Xiaohua Ji, Shengyan Yin, Zhen Zhang, Ruihua Dong, Zheng Zhao, Ben Zhong Tang Small.2025;[Epub] CrossRef
Liver biopsy in the modern era: from traditional techniques to artificial intelligence and multi-omics integration Nasar Alwahaibi, Maryam Alwahaibi Frontiers in Medicine.2025;[Epub] CrossRef
Background/Aims Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is often asymptomatic and can go undiagnosed for years, leading to underuse of HCC surveillance in clinical practice. We characterized the frequency and associated factors of unrecognized cirrhosis in a national sample of patients with HCC from the United States.
Methods HCC patients aged 68 years and older, diagnosed during 2011 to 2015 were included from the SEERMedicare Linked Database. If cirrhosis was diagnosed within 6 months immediately preceding HCC diagnosis or after HCC diagnosis, cases were categorized as unrecognized cirrhosis. Factors associated with unrecognized cirrhosis were identified using logistic regression analyses. Factors associated with overall survival were evaluated using Cox regression analyses.
Results Among 5,098 HCC patients, 74.8% patients had cirrhosis. Among those with cirrhosis, 57.4% had unrecognized cirrhosis, with the highest proportion (76.3%) among those with NAFLD-related HCC. Male sex (aOR: 2.12, 95% CI: 1.83–2.46), non-Hispanic Black race (aOR: 1.93, 95% CI: 1.45–2.57), and NAFLD etiology (aOR: 4.46, 95% CI: 3.68–5.41) were associated with having unrecognized cirrhosis. Among NAFLD-related HCC patients, male sex (aOR: 2.32, 95% CI: 1.71–3.14) was associated with unrecognized cirrhosis. Unrecognized cirrhosis was independently associated with worse overall survival (aHR: 1.17, 95% CI: 1.08–1.27) compared to recognized cirrhosis.
Conclusions Unrecognized cirrhosis is common in NAFLD-related HCC, particularly among male and Black patients, highlighting these groups as important intervention targets to improve HCC surveillance uptake and outcomes.
Citations
Citations to this article as recorded by
Disentangling the Effect of BMI on Hepatocellular Carcinoma From Cirrhosis With Multivariable Mendelian Randomization Apostolos Gkatzionis, Eleanor Sanderson, George Davey Smith, Stefan Stender, Helene Gellert‐Kristensen Liver International.2026;[Epub] CrossRef
Detailed Racial/Ethnic Disparities in Hepatocellular Carcinoma Risk With an Electronic Health Record–Based Cohort Mindy C. DeRouen, Caroline A. Thompson, Alison J. Canchola, Alyssa Cortella, Terri Rice, Pushkar Inamdar, Sixiang Nie, Jane Vu, Pragati Kenkare, Janet N. Chu, Anna D. Rubinsky, Yihe G. Daida, Chanda Ho, Su-Ying Liang, Hashem B. El-Serag, Michele M. Tana, Clinical Gastroenterology and Hepatology.2026;[Epub] CrossRef
Access to Evaluation for Liver Transplantation in the Veterans Health Administration Vera Yakovchenko, Michael F. Chang, Ruben Hernaez, Joseph A. Awad, Jennifer Anwar, Anna Nobbe, Heather McCurdy, Pratima Sharma, Patrick Spoutz, Manimegalai Murugavel, Mark A. Wilson, Jason A. Dominitz, Heather M. Patton, Megan A. Adams, Timothy R. Morgan, Digestive Diseases and Sciences.2025; 70(2): 552. CrossRef
Reply to: “A machine learning model to predict liver-related outcomes after the functional cure of chronic hepatitis B: Is cirrhosis driving the performance?” Moon Haeng Hur, Jeong-Hoon Lee Journal of Hepatology.2025; 82(3): e143. CrossRef
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang Clinical and Molecular Hepatology.2025; 31(Suppl): S228. CrossRef
Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation Federico Carbone, Jean‐Pierre Després, John P. A. Ioannidis, Ian J. Neeland, Gabriella Garruti, Luca Busetto, Luca Liberale, Stefano Ministrini, Gemma Vilahur, Thomas H. Schindler, Maria Paula Macedo, Agostino Di Ciaula, Marcin Krawczyk, Andreas Geier, Gy European Journal of Clinical Investigation.2025;[Epub] CrossRef
Exploring the factors affecting the occurrence of postoperative MVI and the prognosis of hepatocellular carcinoma patients treated with hepatectomy: A multicenter retrospective study Jilin Yang, Junlin Qian, Zhao Wu, Wenjian Zhang, Zexin Yin, Wei Shen, Kun He, Yongzhu He, Liping Liu Cancer Medicine.2024;[Epub] CrossRef
Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu Medicine.2023; 102(32): e34637. CrossRef
First
Prev
